aTYR PHARMA (ATYR) Shares Outstanding (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Shares Outstanding (Entity) came in at $98.1 million in Q1 2026, up 10.17% YoY from $89.0 million in Q1 2025, and little changed on a QoQ basis from $98.0 million in Q4 2025.
aTYR PHARMA (ATYR) Shares Outstanding (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Shares Outstanding (Entity) data on file, last reported at $98.1 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 10.17% year-over-year to $98.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.1 million (up 10.17% YoY) and the FY2025 annual result came in at $98.0 million, up 16.65% from the prior year.
- Shares Outstanding (Entity) steadied at $98.1 million in Q1 2026, from $98.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $98.1 million in Q1 2026 to a low of $28.1 million in Q1 2022.
- A 5-year average of $65.6 million and a median of $68.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 114.54% — and 2026, when it advanced 10.17%.
- Tracing ATYR's Shares Outstanding (Entity) over 5 years: stood at $29.5 million in 2022, then surged by 114.54% to $63.3 million in 2023, then jumped by 32.79% to $84.0 million in 2024, then gained by 16.65% to $98.0 million in 2025, then rose by 0.02% to $98.1 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $98.1 million (Q1 2026), $98.0 million (Q4 2025), and $98.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 98.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.07 Mn |
| Mar 31, 2026 | 98.04 Mn |
| Dec 31, 2025 | 92.99 Mn |
| Sep 30, 2025 | 97.15 Mn |
| Jun 30, 2025 | 90.12 Mn |
| Mar 31, 2025 | 86.49 Mn |
| Dec 31, 2024 | 74.26 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Jun 30, 2024 | 72.28 Mn |
| Mar 31, 2024 | 66.08 Mn |
| Dec 31, 2023 | 53.61 Mn |
| Sep 30, 2023 | 57.89 Mn |
| Jun 30, 2023 | 55.14 Mn |
| Mar 31, 2023 | 41.90 Mn |
| Dec 31, 2022 | 28.42 Mn |
| Sep 30, 2022 | 28.66 Mn |
| Jun 30, 2022 | 28.06 Mn |
| Mar 31, 2022 | 27.82 Mn |
| Dec 31, 2021 | 19.08 Mn |
| Sep 30, 2021 | 18.16 Mn |